COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Oral Bioavailability of Two Solid Formulations of GLPG0259.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01322451
Recruitment Status : Completed
First Posted : March 24, 2011
Last Update Posted : March 24, 2011
Information provided by:
Galapagos NV

Brief Summary:
The purpose of the study is to evaluate the relative bioavailability of two solid oral formulations of GLPG0259 administered after a meal.

Condition or disease Intervention/treatment Phase
Healthy Drug: GLPG0259 fumarate Drug: GLPG0259 free base Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: A Randomized, Open Label, 2-way Crossover Study to Compare the Oral Bioavailability of 2 Solid Dose Formulations of GLPG0259 After Single-dose Intake in Healthy Subjects
Study Start Date : November 2010
Actual Primary Completion Date : December 2010
Actual Study Completion Date : January 2011

Arm Intervention/treatment
Experimental: Single oral dose, single capsule Drug: GLPG0259 free base
single oral dose, GLPG0259, 50 mg solid formulation

Experimental: Single oral dose, two capsules Drug: GLPG0259 fumarate
single oral dose, two capsules each containing 25 mg of GLPG0259 fumarate

Primary Outcome Measures :
  1. Bioavailability of two solid dosage formulations of GLPG0259 [ Time Frame: up to 96 hours postdose ]

Secondary Outcome Measures :
  1. Safety and tolerability of GLPG0259 [ Time Frame: up to 96 hours postdose ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • healthy male, age 18-50 years
  • BMI between 18-30 kg/m², inclusive.

Exclusion Criteria:

  • significantly abnormal platelet function or coagulopathy
  • smoking
  • drug or alcohol abuse

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01322451

Layout table for location information
SGS Stuivenberg
Antwerp, Belgium
Sponsors and Collaborators
Galapagos NV
Layout table for investigator information
Study Director: Johan Beetens, PharmD, PhD Galapagos NV
Principal Investigator: Lien Gheyle, MD SGS Stuivenberg
Layout table for additonal information
Responsible Party: Senior Vice President Development, Galapagos NV Identifier: NCT01322451    
Other Study ID Numbers: GLPG0259-CL-104
2010-022456-23 ( EudraCT Number )
First Posted: March 24, 2011    Key Record Dates
Last Update Posted: March 24, 2011
Last Verified: March 2011
Keywords provided by Galapagos NV: